Department of Vascular Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH, USA.
Vasc Endovascular Surg. 2023 Aug;57(6):564-573. doi: 10.1177/15385744231154084. Epub 2023 Feb 27.
This study aims to identify the clinical variables which are predictive for the benefit of concomitant distal revascularization (DR) to prevent Chronic limb-threatening ischemia (CLTI) progression and the need for major limb amputation.
This is a retrospective cohort study of patients who presented with lower limb ischemia and required at least femoral endarterectomy (FEA), recruited over a period of 15 years (2002-2016). The patient cohort was divided into three groups based on the type of intervention: A (FEA alone), B (FEA + catheter-based intervention/(CBI)), and C (FEA + surgical bypass (SB)). The primary endpoint was to identify independent predictors for the use of concomitant DR (CBI or SB). Secondary endpoints were amputation rate, length of stay, mortality rate, postoperative ankle-brachial index and complications, readmission rate, re-intervention rate, resolution of symptoms and wound status.
A total of 400 patients were included, 68.0% were males. Most presenting limbs were at Rutherford class (RC) III and WIfI stage 2, with an ankle-brachial index (ABI) of .47 ± .21 and a TASC II class C lesion. No significant differences were found in the primary-assisted and secondary patency rates between the three groups ( > .05, in all). In the multivariate analyses, clinical variables associated with DR were hyperlipidemia (hazard ratio (HR) 2.1-2.2), TASC II D (HR 2.62), Rutherford class 4 (HR 2.3) and 5 (HR 3.7), as well as WIfI stage ≥3 (HR 1.48).
Femoral endarterectomy is sufficient to treat intermittent claudication. However, patients in whom rest pain, tissue loss or TASC II D anatomic lesion severity are present may benefit from concomitant distal revascularization. Taking into consideration the overall assessment of operative risk factors for each individual patient, proceduralists should have a lower threshold for performing early or concomitant distal revascularization to reduce CLTI progression including additional tissue loss and/or major limb amputation.
本研究旨在确定具有预测价值的临床变量,以评估同期远端血运重建(DR)对预防慢性肢体威胁性缺血(CLTI)进展和大肢体截肢的必要性。
这是一项回顾性队列研究,纳入了 15 年来(2002-2016 年)因下肢缺血而需要至少股动脉内膜切除术(FEA)的患者。根据干预方式,将患者分为三组:A 组(仅行 FEA)、B 组(FEA+基于导管的干预/ CBI)和 C 组(FEA+手术旁路(SB))。主要终点是确定同期行 DR(CBI 或 SB)的独立预测因素。次要终点包括截肢率、住院时间、死亡率、术后踝肱指数和并发症、再入院率、再干预率、症状缓解和伤口状况。
共纳入 400 例患者,68.0%为男性。大多数初诊肢体处于 Rutherford 分级(RC)III 级和 WIfI 分期 2 级,踝肱指数(ABI)为 0.47±0.21,TASC II 分级 C 型病变。三组间主要和次要通畅率无显著差异(>0.05,均 P>0.05)。多变量分析显示,与 DR 相关的临床变量包括高脂血症(危险比(HR)2.1-2.2)、TASC II D(HR 2.62)、RC 4 级(HR 2.3)和 5 级(HR 3.7)以及 WIfI 分期≥3 级(HR 1.48)。
FEA 足以治疗间歇性跛行。然而,对于存在静息痛、组织缺失或 TASC II 解剖学病变严重程度的患者,同期行远端血运重建可能获益。考虑到每位患者手术风险因素的综合评估,术者应降低早期或同期行远端血运重建的门槛,以降低 CLTI 进展,包括进一步的组织缺失和/或大肢体截肢。